TG Therapeutics (TGTX) Announces Presentation of Preclinical TGR-1202 Data; Dose Dependent Cytotoxicity Noted
Tweet Send to a Friend
TG Therapeutics, Inc. (Nasdaq: TGTX) announced the presentation of preclinical data describing the differential regulation of human T-cells by TGR-1202 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
